Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve.
作者信息
Galiuto Leonarda, Patrono Carlo
机构信息
Assistant Professor of Cardiology, Fondazione Policlinico A. Gemelli-IRCSS, Catholic University of the Sacred Heart Rome, Italy.
Adjunct Professor of Pharmacology, Catholic University, School of Medicine, Italy and Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA.
出版信息
Eur Heart J. 2021 Feb 21;42(8):811-812. doi: 10.1093/eurheartj/ehaa1075.
PMID:33398340
Abstract
摘要
相似文献
1
Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve.利伐沙班，心房颤动合并生物瓣二尖瓣置换术后患者的一种新选择。
Eur Heart J. 2021 Feb 21;42(8):811-812. doi: 10.1093/eurheartj/ehaa1075.
2
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者
N Engl J Med. 2021 Mar 11;384(10):973-974. doi: 10.1056/NEJMc2035891.
3
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者
N Engl J Med. 2021 Mar 11;384(10):975. doi: 10.1056/NEJMc2035891.
4
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换术后患者
N Engl J Med. 2021 Mar 11;384(10):974-975. doi: 10.1056/NEJMc2035891.
5
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve.利伐沙班用于心房颤动合并生物瓣二尖瓣置换患者
N Engl J Med. 2021 Mar 11;384(10):974. doi: 10.1056/NEJMc2035891.
6
In patients with AF and a bioprosthetic mitral valve, rivaroxaban was noninferior to warfarin for time to clinical events.在合并有房颤和生物瓣二尖瓣置换的患者中，利伐沙班用于临床事件时间的非劣效于华法林。
Ann Intern Med. 2021 Apr;174(4):JC43. doi: 10.7326/ACPJ202104200-043. Epub 2021 Apr 6.
7
Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. Reply.利伐沙班用于心房颤动合并生物瓣二尖瓣置换患者。回复
N Engl J Med. 2021 Mar 11;384(10):975-976. doi: 10.1056/NEJMc2035891.
8
Is this the beginning of end for warfarin in bioprosthetic mitral valve recipients with atrial fibrillation? - New insights from RIVER trial.房颤合并生物瓣二尖瓣置换术后患者华法林的时代是否即将终结？——RIVER 试验的新见解。
Indian Heart J. 2021 Jul-Aug;73(4):516-517. doi: 10.1016/j.ihj.2021.06.019. Epub 2021 Jul 1.
9
10
Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses.利伐沙班预防非瓣膜性心房颤动患者的卒中和全身性栓塞：ROCKET AF试验及其亚组分析的临床意义
Am J Cardiovasc Drugs. 2015 Dec;15(6):395-401. doi: 10.1007/s40256-015-0127-2.
Zotero 插件